feeling ill; felt awful; did not feel normal; Red rash, red blotches on her flesh where she had injected in thigh; Red rash, red blotches on her flesh where she had injected in thigh; vaccine injected into her thigh; Initial information received on 09-Dec-2019 regarding an unsolicited valid  non-serious case received as courtesy case  from a consumer/non-healthcare professional via specialty pharmacy.  This case involves a 73 years old female patient who was feeling ill, felt awful; did not feel normal, red rash, red blotches on her flesh where she had injected in thigh and reported vaccine injected into her thigh , after receiving vaccine INFLUENZA VACCINE and while treated with ABALOPARATIDE [TYMLOS].  The patient's past medical history, medical treatment(s), vaccination(s), concurrent conditions, concomitant medications  and family history were not reported.   Ona n unknown date in Jan-2019, the patient started taking TYMLOS (ABALOPARATIDE) Injection, at dose of  80 ug daily (QD) via  subcutaneous (with an unknown batch number) and it was indicated for Postmenopausal women with osteoporosis at high risk for fracture (Osteoporosis postmenopausal). On 06-Jul-2022, the patient received a  dose of suspect INFLUENZA VACCINE produced by unknown manufacturer, with an unknown formulation and strength, ( lot number and expiry date: not reported)  via unknown route for  prophylaxis against flu (Antiviral prophylaxis). It was reported that it was injected into her thigh (product administered at inappropriate site) (latency: same day)   On an unknown date the patient developed a non-serious event of  feeling ill (illness) , felt awful; did not feel normal (feeling abnormal) (unknown latency) following the first dose intake  of ABALOPARATIDE and Influenza Vaccine.  On 07-JUL-2022,  the patient developed a non-serious  event of red rash, red blotches on her flesh where she had injected in thigh (injection site rash)  (rash macular) (latency: 1 day) following the first dose intake of Influenza Vaccine and (latency: 3 years and 6 month approximately) following the first dose intake of ABALOPARATIDE. it was reported that when patient was injected on 07-Jul-2022 and 08-Jul-2022, almost immediately after injection did not feel normal.  it was stated by the patient that shipment was making her ill because Tymlos can get contaminated and she had never had this kind of reaction to Tymlos before   Action taken : no action taken for  ABALOPARATIDE (TYMLOS);  not applicable for INFLUENZA VACCINE (INFLUENZA VACCINE) for all the events.  Corrective treatment: not reported for all the events  Outcome: unknown for all the events   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.